Endocytosis of HIV: Anything goes

Trends in Microbiology

Volumn 18, Issue 12, 2010, Pages 543-551

  Permanyer, Marc ^a   Ballana, Ester ^a   Esté, José A ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CLATHRIN; ENFUVIRTIDE; MARAVIROC;

BINDING KINETICS; CD4+ T LYMPHOCYTE; ENDOCYTOSIS; ENDOSOME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS TRANSMISSION; VIRUS VIRULENCE;

CD4-POSITIVE T-LYMPHOCYTES; ENDOCYTOSIS; HIV; HIV INFECTIONS; HUMANS; IMMUNE EVASION; VIRUS INTERNALIZATION;

EID: 78649316355     PISSN: 0966842X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tim.2010.09.003     Document Type: Review

References (59)

1. Esté J.A., Cihlar T. Current challenges in antiretoviral research and treatment. Antiviral Res. 2010, 85:26-33.
2. Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res. 2010, 85:1-18.
3. Este J.A., Telenti A. HIV entry inhibitors. Lancet 2007, 370:81-88.
4. Tilton J.C., Doms R.W. Entry inhibitors in the treatment of HIV-1 infection. Antiviral Res. 2010, 85:91-100.
5. Ugolini S., et al. HIV-1 attachment: another look. Trends Microbiol. 1999, 7:144-149.
6. Stein B.S., et al. pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane. Cell 1987, 49:659-668.
7. Miyauchi K., et al. HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 2009, 137:433-444.
8. Maddon P.J., et al. HIV infection does not require endocytosis of its receptor, CD4. Cell 1988, 54:865-874.
9. Bedinger P., et al. Internalization of the human immunodeficiency virus does not require the cytoplasmic domain of CD4. Nature 1988, 334:162-165.
10. Kielian M., Jungerwirth S. Mechanisms of enveloped virus entry into cells. Mol. Biol. Med. 1990, 7:17-31.
11. Skehel J.J., Wiley D.C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 2000, 69:531-569.
12. Bomsel M. Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat. Med. 1997, 3:42-47.
13. Fackler O.T., Peterlin B.M. Endocytic entry of HIV-1. Curr. Biol. 2000, 10:1005-1008.
14. Goto T., et al. The life-cycle of human immunodeficiency virus type 1. Micron 1998, 29:123-138.
15. Liu N.Q., et al. Human immunodeficiency virus type 1 enters brain microvascular endothelia by macropinocytosis dependent on lipid rafts and the mitogen- activated protein kinase signaling pathway. J. Virol. 2002, 76:6689-6700.
16. Marechal V., et al. Human immunodeficiency virus type 1 entry into macrophages mediated by macropinocytosis. J. Virol. 2001, 75:11166-11177.
17. Schaeffer E., et al. Compensatory link between fusion and endocytosis of human immunodeficiency virus type 1 in human CD4 T lymphocytes. J. Virol. 2004, 78:1375-1383.
18. Blanco J., et al. High level of coreceptor-independent HIV transfer induced by contacts between primary CD4 T cells. J. Biol. Chem. 2004, 279:51305-51314.
19. Pauza C.D., Price T.M. Human immunodeficiency virus infection of T cells and monocytes proceeds via receptor-mediated endocytosis. J. Cell Biol. 1988, 107:959-968.
20. Campbell E.M., Hope T.J. Live cell imaging of the HIV-1 life cycle. Trends Microbiol. 2008, 16:580-587.
21. Conner S.D., Schmid S.L. Regulated portals of entry into the cell. Nature 2003, 422:37-44.
22. Marsh M., Helenius A. Virus entry: open sesame. Cell 2006, 124:729-740.
23. Mercer J., et al. Virus entry by endocytosis. Annu. Rev. Biochem. 2010, 79:803-833.
24. Vidricaire G., et al. The low viral production in trophoblastic cells is due to a high endocytic internalization of the human immunodefiency virus type 1 and can be overcome by the pro-inflammatory cytokines TNF-alpha and IL-1. J. Biol. Chem. 2003, 25:25.
25. Fredericksen B.L., et al. Inhibition of endosomal/lysosomal degradation increases the infectivity of human immunodeficiency virus. J. Virol. 2002, 76:11440-11446.
26. Hubner W., et al. Quantitative 3D video microscopy of HIV transfer across T cell virological synapses. Science 2009, 323:1743-1747.
27. Jolly C., et al. HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J. Exp. Med. 2004, 199:283-293.
28. Martin N., Sattentau Q. Cell-to-cell HIV-1 spread and its implications for immune evasion. Curr. Opin. HIV AIDS 2009, 4:143-149.
29. McDonald D., et al. Visualization of the intracellular behavior of HIV in living cells. J. Cell Biol. 2002, 159:441-452.
30. Bosch B., et al. Inhibition of coreceptor independent cell-to-cell HIV-1 transmission by a CD4-IgG2 fusion protein. Antimicrob. Agents Chemother. 2005, 49:4296-4304.
31. Ruggiero E., et al. Virological consequences of early events following cell-cell contact between human immunodeficiency virus type 1-infected and uninfected CD4+ cells. J. Virol. 2008, 82:7773-7789.
32. Daecke J., et al. Involvement of clathrin-mediated endocytosis in human immunodeficiency virus type 1 entry. J. Virol. 2005, 79:1581-1594.
33. Bosch B., et al. A clathrin-dynamin-dependent endocytic pathway for the uptake of HIV-1 by direct T cell-T cell transmission. Antiviral Res. 2008, 80:185-193.
34. Macia E., et al. Dynasore, a cell-permeable inhibitor of dynamin. Dev. Cell 2006, 10:839-850.
35. Uchil P.D., Mothes W. HIV entry revisited. Cell 2009, 137:402-404.
36. Martin N., et al. Virological synapse-mediated spread of human immunodeficiency virus type 1 between T cells is sensitive to entry inhibition. J. Virol. 2010, 84:3516-3527.
37. Chen P., et al. Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses. J. Virol. 2007, 81:12582-12595.
38. Arthos J., et al. HIV-1 envelope protein binds to and signals through integrin [alpha]4[beta]7, the gut mucosal homing receptor for peripheral T cells. Nat. Immunol. 2008, 9:301-309.
39. Mondor I., et al. Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans. J. Virol. 1998, 72:3623-3634.
40. Saphire A.C., et al. Syndecans serve as attachment receptors for human immunodeficiency virus type 1 on macrophages. J. Virol. 2001, 75:9187-9200.
41. de Witte L., et al. Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:19464-19469.
42. Geijtenbeek T.B., et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000, 100:587-597.
43. Lambert A.A., et al. The C-type lectin surface receptor DCIR acts as a new attachment factor for HIV-1 in dendritic cells and contributes to trans- and cis-infection pathways. Blood 2008, 112:1299-1307.
44. Yu D., et al. The HIV envelope but not VSV glycoprotein is capable of mediating HIV latent infection of resting CD4 T cells. PLoS Pathog. 2009, 5:e1000633.
45. Puigdomenech I., et al. HIV transfer between CD4 T cells does not require LFA-1 binding to ICAM-1 and is governed by the interaction of HIV envelope glycoprotein with CD4. Retrovirology 2008, 5:32.
46. Clotet-Codina I., et al. HIV endocytosis after dendritic cell to T cell viral transfer leads to productive virus infection. Antiviral Res. 2009, 83:94-98.
47. Si Z., et al. Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:5036-5041.
48. Gonzalez-Ortega E., et al. ADS-J1 inhibits HIV-1 entry by interacting with gp120 and does not block the fusion-active gp41 core formation. Antimicrob. Agents Chemother. 2010, 54:4487-4492.
49. Massanella M., et al. Antigp41 antibodies fail to block early events of virological synapses but inhibit HIV spread between T cells. AIDS 2009, 23:183-188.
50. Blanco J., et al. Multiparametric assay to screen and dissect the mode of action of anti-human immunodeficiency virus envelope drugs. Antimicrob. Agents Chemother. 2005, 49:3926-3929.
51. Bosch B., et al. Inhibition of human immunodeficiency virus type 1 infection in macrophages by an alpha-v integrin blocking antibody. Antiviral Res. 2006, 69:173-180.
52. Miyauchi K., et al. Early steps of HIV-1 fusion define the sensitivity to inhibitory peptides that block 6-helix bundle formation. PLoS Pathog. 2009, 5:e1000585.
53. Blanco J., et al. R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism. J. Leukoc. Biol. 2004, 76:804-811.
54. Barretina J., et al. Anti-HIV-1 activity of enfuvirtide (T-20) by inhibition of bystander cell death. Antivir Ther. 2003, 8:155-161.
55. Greene W.C., et al. Novel targets for HIV therapy. Antiviral Res. 2008, 80:251-265.
56. Adamson C.S., Freed E.O. Novel approaches to inhibiting HIV-1 replication. Antiviral Res. 2010, 85:119-141.
57. Robinson M.S. Adaptable adaptors for coated vesicles. Trends Cell Biol. 2004, 14:167-174.
58. Ballana E., et al. Cell adhesion through alphaV-containing integrins is required for efficient HIV-1 infection in macrophages. Blood 2009, 113:1278-1286.
59. Cicala C., et al. The integrin {alpha}4{beta}7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:20877-20882.